Literature DB >> 17502456

Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas.

Tint Lwin1, Lori A Hazlehurst, Sophie Dessureault, Raymond Lai, Wenlong Bai, Eduardo Sotomayor, Lynn C Moscinski, William S Dalton, Jianguo Tao.   

Abstract

Mounting evidence suggests that dynamic interactions between a tumor and its microenvironment play a critical role in tumor development, cell-cycle progression, and response to therapy. In this study, we used mantle cell lymphoma (MCL) as a model to characterize the mechanisms by which stroma regulate cell-cycle progression. We demonstrated that adhesion of MCL and other non-Hodgkin lymphoma (NHL) cells to bone marrow stromal cells resulted in a reversible G(1) arrest associated with elevated p27(Kip1) and p21 (WAF1) proteins. The adhesion-mediated p27(Kip1) and p21 increases were posttranslationally regulated via the down-regulation of Skp2, a subunit of SCF(Skp2) ubiquitin ligase. Overexpression of Skp2 in MCL decreased p27(Kip1), whereas inhibition of Skp2 by siRNA increased p27(Kip1) and p21 levels. Furthermore, we found cell adhesion up-regulated Cdh1 (an activating subunit of anaphase-promoting complex [APC] ubiquitin ligase), and reduction of Cdh1 by siRNA induced Skp2 accumulation and hence p27(Kip1) degradation, thus implicating Cdh1 as an upstream effector of the Skp2/p27(Kip1) signaling pathway. Overall, this report, for the first time, demonstrates that cell-cell contact controls the tumor cell cycle via ubiquitin-proteasome proteolytic pathways in MCL and other NHLs. The understanding of this novel molecular pathway may prove valuable in designing new therapeutic approaches for modifying tumor cell growth and response to therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17502456      PMCID: PMC1975846          DOI: 10.1182/blood-2006-11-060350

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

Review 1.  Regulation of the cell cycle at the G1-S transition by proteolysis of cyclin E and p27Kip1.

Authors:  K I Nakayama; S Hatakeyama; K Nakayama
Journal:  Biochem Biophys Res Commun       Date:  2001-04-13       Impact factor: 3.575

2.  SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27.

Authors:  A C Carrano; E Eytan; A Hershko; M Pagano
Journal:  Nat Cell Biol       Date:  1999-08       Impact factor: 28.824

Review 3.  Role of cyclin-dependent kinases and their inhibitors in cellular differentiation and development.

Authors:  S P Chellappan; A Giordano; P B Fisher
Journal:  Curr Top Microbiol Immunol       Date:  1998       Impact factor: 4.291

Review 4.  The metaphase-to-anaphase transition: avoiding a mid-life crisis.

Authors:  O Cohen-Fix; D Koshland
Journal:  Curr Opin Cell Biol       Date:  1997-12       Impact factor: 8.382

5.  Identification of a novel ubiquitin-conjugating enzyme involved in mitotic cyclin degradation.

Authors:  H Yu; R W King; J M Peters; M W Kirschner
Journal:  Curr Biol       Date:  1996-04-01       Impact factor: 10.834

6.  Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR).

Authors:  L A Hazlehurst; J S Damiano; I Buyuksal; W J Pledger; W S Dalton
Journal:  Oncogene       Date:  2000-09-07       Impact factor: 9.867

Review 7.  Integrin-mediated drug resistance in multiple myeloma.

Authors:  J S Damiano; W S Dalton
Journal:  Leuk Lymphoma       Date:  2000-06

8.  Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta.

Authors:  I Reynisdóttir; K Polyak; A Iavarone; J Massagué
Journal:  Genes Dev       Date:  1995-08-01       Impact factor: 11.361

9.  Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27.

Authors:  M Pagano; S W Tam; A M Theodoras; P Beer-Romero; G Del Sal; V Chau; P R Yew; G F Draetta; M Rolfe
Journal:  Science       Date:  1995-08-04       Impact factor: 47.728

10.  Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein.

Authors:  X Zhu; M Ohtsubo; R M Böhmer; J M Roberts; R K Assoian
Journal:  J Cell Biol       Date:  1996-04       Impact factor: 10.539

View more
  46 in total

Review 1.  APC/C-Cdh1: from cell cycle to cellular differentiation and genomic integrity.

Authors:  Xinxian Qiao; Liyong Zhang; Armin M Gamper; Takeo Fujita; Yong Wan
Journal:  Cell Cycle       Date:  2010-10-11       Impact factor: 4.534

Review 2.  Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.

Authors:  Patricia Pérez-Galán; Martin Dreyling; Adrian Wiestner
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

3.  Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells.

Authors:  Rekha Rao; Srilatha Nalluri; Warren Fiskus; Andrew Savoie; Kathleen M Buckley; Kyungsoo Ha; Ramesh Balusu; Atul Joshi; Veena Coothankandaswamy; Jianguo Tao; Eduardo Sotomayor; Peter Atadja; Kapil N Bhalla
Journal:  Clin Cancer Res       Date:  2010-07-20       Impact factor: 12.531

4.  Sam68 regulates cell proliferation and cell adhesion-mediated drug resistance (CAM-DR) via the AKT pathway in non-Hodgkin's lymphoma.

Authors:  Yaxun Wu; Xiaohong Xu; Xiaobing Miao; Xinghua Zhu; Haibing Yin; Yunhua He; Chunsun Li; Yushan Liu; Yali Chen; Xiaoyun Lu; Yuchan Wang; Song He
Journal:  Cell Prolif       Date:  2015-10-19       Impact factor: 6.831

5.  Bone marrow stromal cells induced activation of nuclear factor κB signaling protects non-Hodgkin's B lymphoma cells from apoptosis.

Authors:  Tuo Su; Jiakai Li; Mingming Meng; Sheng Zhao; Yali Xu; Xinmin Ding; Hong Jiang; Xiaorong Ma; Jin Qian; Wei Han; Lixin Sun; Xiaobin Li; Zuojun Liu; Lei Pan; Xinying Xue
Journal:  Tumour Biol       Date:  2016-02-12

6.  Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy.

Authors:  Qing Chen; Weilin Xie; Deborah J Kuhn; Peter M Voorhees; Antonia Lopez-Girona; Derek Mendy; Laura G Corral; Veronique Plantevin Krenitsky; Weiming Xu; Laure Moutouh-de Parseval; David R Webb; Frank Mercurio; Keiichi I Nakayama; Keiko Nakayama; Robert Z Orlowski
Journal:  Blood       Date:  2008-02-27       Impact factor: 22.113

Review 7.  Targeting the tumour stroma to improve cancer therapy.

Authors:  Kenneth C Valkenburg; Amber E de Groot; Kenneth J Pienta
Journal:  Nat Rev Clin Oncol       Date:  2018-06       Impact factor: 66.675

Review 8.  Environment-mediated drug resistance: a major contributor to minimal residual disease.

Authors:  Mark B Meads; Robert A Gatenby; William S Dalton
Journal:  Nat Rev Cancer       Date:  2009-08-20       Impact factor: 60.716

9.  A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas.

Authors:  Tint Lwin; Xiaohong Zhao; Fengdong Cheng; Xinwei Zhang; Andy Huang; Bijal Shah; Yizhuo Zhang; Lynn C Moscinski; Yong Sung Choi; Alan P Kozikowski; James E Bradner; William S Dalton; Eduardo Sotomayor; Jianguo Tao
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

10.  microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma.

Authors:  Jian-Jun Zhao; Jianhong Lin; Tint Lwin; Hua Yang; Jianping Guo; William Kong; Sophie Dessureault; Lynn C Moscinski; Dorna Rezania; William S Dalton; Eduardo Sotomayor; Jianguo Tao; Jin Q Cheng
Journal:  Blood       Date:  2010-01-19       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.